License and Collaboration Agreement by and between Five Prime Therapeutics, Inc. and Human Genome Sciences, Inc.License and Collaboration Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
• HGS acquires exclusive rights to develop and commercialize FivePrime’s FP-1039 in the United States, Canada and European Union
ContractExclusive License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • California
*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , 2013 between Five Prime Therapeutics, Inc., a Delaware corporation (the “Company”), and , an individual (“Indemnitee”). This Agreement will become effective only upon the effectiveness of the Company’s registration statement on Form S-1 in connection with the Company’s initial public offering. This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement.
Research Collaboration and License AgreementResearch Collaboration and License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
Exclusive License AgreementExclusive License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • California
*** INDICATES ONE PAGE OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
AMENDMENT No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (Muscle Diseases Research Program Expansion)Research Collaboration and License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This AMENDMENT NO. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Amendment No. 1”), effective as of the 17th day of May, 2011 (the “Amendment No. 1 Effective Date”), is made by and between GlaxoSmithKline LLC, a Delaware limited liability company having a place of business at One Franklin Plaza, Philadelphia, PA 19101 (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at Two Corporate Drive, South San Francisco, CA 94080 (“FivePrime”). GSK and FivePrime are referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between GlaxoSmithKline LLC and Five Prime Therapeutics, Inc.Research Collaboration and License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
This Research Collaboration and License Agreement (the “Agreement”) is effective as of July 29, 2010 (the “Effective Date”) and is entered into by and between GlaxoSmithKline LLC, a Delaware limited liability company having a place of business at One Franklin Plaza, Philadelphia, PA 19101 (“GSK”), and Five Prime Therapeutics, Inc., a Delaware corporation having a place of business at 1650 Owens Street, Suite 200, San Francisco, CA (“FivePrime”). GSK and FivePrime are referred to individually as a “Party” and collectively as the “Parties.”
NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • New York
THIS NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of February 6, 2012 (the “Effective Date”), is entered into by and among BioWa, Inc., a Delaware corporation, with a principal place of business at 212 Carnegie Center, Suite 101, Princeton, New Jersey 08540, USA (“BioWa”); Lonza Sales AG, a Swiss corporation, with a principal place of business at Munchensteinerstrasse 38, Basel, CH-4002 Switzerland (“Lonza” and, together with BioWa, the “Licensor”); and Five Prime Therapeutics, Inc., a Delaware corporation, with a place of business at Two Corporate Drive, South San Francisco, California 94080, USA (“Licensee”). Lonza, BioWa, Licensor or Licensee may hereafter be referred to individually as a “Party” and collectively as the “Parties.”
RESPIRATORY DISEASES RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Glaxo Group Limited and Five Prime Therapeutics, Inc.Respiratory Diseases Research Collaboration and License Agreement • August 16th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations • Delaware
and brings tremendous expertise to the collaboration. Our existing GSK alliance to discover products for skeletal muscle disorders, which was recently expanded last year, is making great progress, so we are extremely pleased to enter into this additional collaboration.” said Lewis T. “Rusty” Williams, MD, PhD, Founder, President and CEO of FivePrime.
